Promising biological therapies for ulcerative colitis: A review of the literature

Akiho, Hirotada; Yokoyama, Akira; Abe, Shuichi; Nakazono, Yuichi; Murakami, Masatoshi; Otsuka, Yoshihiro; Fukawa, Kyoko; Mitsuru, Esaki; Niina, Yusuke; Ogino, Hitoshi

doi:10.4291/wjgp.v6.i4.219

Cited by 47 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These are antibodies which target the leukocyte adhesion and trafficking, thereby reducing inflammation. Integrin antagonists have recently shown promising results in induction and maintenance of remission for both CD and UC patients [ 21 ].…”

Section: Integrin Antagonistsmentioning

confidence: 99%

Advances in the development of new biologics in inflammatory bowel disease

Ungar

Kopylov

2016

aog

View full text Add to dashboard Cite

Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.

show abstract

Section: Integrin Antagonistsmentioning

confidence: 99%

Advances in the development of new biologics in inflammatory bowel disease

Ungar

Kopylov

2016

aog

View full text Add to dashboard Cite

show abstract

“…In addition to the extent of involvement, people may also be characterized by the severity of their disease: Mild, moderate and severe [4]. In spite of unknown causes UC is unknown; however, there are several factors such as disorder of immune system, genetics, abnormality of bacterial flora in the gut, and environmental factors are usually having a relation with UC [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Epidemiological and Clinical Aspects of Ulcerative Colitis in Mosul city, Iraq

Babakir‐Mina

2019

KJAR

View full text Add to dashboard Cite

Ulcerative Colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract with heterogeneous disease presentation. A cross-sectional descriptive study was undertaken in Mosul GeneralHospital. The study was conducted using two distinct methodologies. An observational checklist was used by the researcher to assess the patients' characteristics and factors related to UC from 200 hospitalized patients from December 2018 to April 2019. Data were entered into spreadsheets and analyzed in Statistical Package for Social Sciences (SPSS) version 22. The results showed that 49.0% of patients was males and 51.0% was female; the mean age was 46.36 years old. Elderly stage (> 45 years of age) makes the highest proportion of the patients 99 (49.5%). The majority of patients was from urban or inside Mosul city center 140 (70%).The study also showed that the more frequency of patients 103 (51.5%) were in severe condition. Patients were used or given more antibiotics, they will be liked to get UC 191 (95.5%) and the relation was found to be statistically significant at (p<0.001). The study showed that 95 (47. moderate 35 (34.3%). Out of 103 severe cases, 60 of them were female. These differences were statistically significant at (p<0.05). In addition, out of 45 female patients were used oral contraceptive pills, 30 (66.7%) of them were in severe cases of UC and followed by 14 (31.1%) were in moderate cases. Majority of patients previously were sensitive to spices 160 (80.0%) and followed by fish and eggs 21 (10.5) 16 (8.0%) respectively. In addition, out of 160 spices sensitive patients, 80 (50.5%) of them were in severe cases and 61 (38.1%) were in moderate cases. Statistically, these differences are significant at (p<0.05). In the conclusion, UC among late adult in our community needs critical care and monitoring. The female patients were at risk of UC especially, who uses oral contraceptive pills. The random and more antibiotic uses are considered as major risk factors lead to cause UC. 5%) of all cases had a previous family history of UC. Out of 102 female patients, 45 (44.1%) were more frequently under uses of contraceptive pills. 60 (58.8%) of patients was in severe cases of UC and followed by

show abstract

“…Ulcerative colitis (UC) is a recurrent, debilitating, and chronic inflammatory disease of the colon and rectum that is characterized by mucosal and submucosal ulceration, diarrhea, and rectal bleeding ( Akiho et al, 2015 ). These symptoms can severely impact patient quality of life.…”

Section: Introductionmentioning

confidence: 99%

Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway

et al. 2017

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a recurrent, chronic intestinal disease. Available treatments for UC are poor effective and/or cause severe adverse events. X-box binding protein 1 (XBP1) and nuclear factor-κB (NF-κB) have been reported to play important roles in UC. Specifically, deletion or downregulation of XBP1 leads to spontaneous enteritis and results in imbalanced secretion of NF-κB and other proinflammatory cytokines. (±)-8-acetonyl-dihydrocoptisine, i.e., (±)-8-ADC, is a monomer semi-synthesized from coptisine. In vitro, (±)-8-ADC activated the transcriptional activity of XBP1, inhibited expression of NF-κB, and reduced production of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β), in lipopolysaccharide-stimulated IEC6 cells. Therefore, silencing XBP1 would reduce the inhibition effect of (±)-8-ADC on NF-κB expression and the cytokines secretion in vitro. In a dextran sulfate sodium-induced colitis mouse model, oral administration of (±)-8-ADC ameliorated weight loss and colon contracture, and decreased the average disease activity index score and pathological damage. Simultaneously, (±)-8-ADC also increased XBP1 expression, and decreased NF-κB expression and secretion of myeloperoxidase, TNF-α, IL-6 and IL-1β in the colon. Therefore, (±)-8-ADC may ameliorate UC via the XBP1-NF-κB pathway and should be considered as a therapeutic candidate for UC.

show abstract

Promising biological therapies for ulcerative colitis: A review of the literature

Cited by 47 publications

References 37 publications

Advances in the development of new biologics in inflammatory bowel disease

Advances in the development of new biologics in inflammatory bowel disease

Epidemiological and Clinical Aspects of Ulcerative Colitis in Mosul city, Iraq

Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway

Contact Info

Product

Resources

About